EZHARMIA valemetostat
Drug Class
EZH1/2 dual inhibitorEZH1/2 双重抑制剂
Mechanism
Selectively inhibits both EZH1 and EZH2 methyltransferases, reducing histone H3K27 trimethylation to suppress lymphoma gene transcription.选择性地抑制 EZH1 和 EZH2 甲基转移酶，减少组蛋白 H3K27 三甲基化水平，以抑制淋巴瘤基因的转录。
Approved Indication
Treatment of adult patients with relapsed or refractory adult T-cell leukemia-lymphoma (ATL) or relapsed or refractory peripheral T-cell lymphoma (PTCL).用于治疗复发或难治性成人 T 细胞白血病/淋巴瘤 (ATL) 或复发或难治性外周 T 细胞淋巴瘤 (PTCL) 患者。
What This Means For Patients
Ezharmia (valemetostat) is a dual EZH1/EZH2 epigenetic inhibitor approved in Japan to treat aggressive T-cell leukemia and lymphomas. By modifying histone markers, it stops malignant gene activation in cancer cells. It is clinically accessible in Boao Lecheng under Hainan's special-import policy.伐美司他（Ezharmia）是在日本获批治疗侵袭性 T 细胞白血病和淋巴瘤的双重 EZH1/EZH2 表观遗传抑制剂。它通过改变组蛋白标记以阻止癌细胞中的恶性基因表达。患者可通过博鳌乐城先行区特许政策使用该药。
Regulatory Approvals
- PMDA — approved (2022) — source
Pivotal Clinical Evidence
- DS3078-A-J101 — Izutsu et al., Blood 2023 (NCT03542188) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.